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High HIV-1 DNA (HIV DNA) levels in peripheral blood mononuclear cells (PBMC) correlate with 
HIV-1-associated dementia (HAD) in patients on highly active antiretroviral therapy (HAART). If this relation-
ship also exists among HAART-naïve patients, then HIV DNA may be implicated in the pathogenesis of HAD. 
In this study, we evaluated the relationship between HIV DNA and cognition in subjects naïve to HAART in a 
neuroAIDS cohort in Bangkok, Thailand. Subjects with and without HAD were recruited and matched for age, 
gender, education, and CD4 cell count. PBMC and cellular subsets were analyzed for HIV DNA using real-time 
PCR. The median log10 HIV DNA copies per 106 PBMC for subjects with HAD (n=15) was 4.27, which was 
higher than that found in subjects without dementia (ND; n=15), 2.28, p<0.001. This finding was unchanged in a 
multivariate model adjusting for plasma HIV-1 RNA levels. From a small subset of individuals, in which ade-
quate number of cells were available, more HIV DNA was in monocytes/macrophages from those with HAD 
compared to those with ND. These results are consistent with a previous report among HAART-experienced 
subjects, thus further implicating HIV DNA in the pathogenesis of HAD. 
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1.  INTRODUCTION 
Complete eradication of the human immunode-
ficiency virus, type 1 (HIV-1) from infected individu-
als is not currently possible due, in part, to continuing 
presence of virus in lymphocytes and cells of the 
macrophage lineage [1-3]. Monocytes/macrophages 
(M/MΦ) are cellular sanctuaries for HIV-1, which re-
main present even in patients with suppressed plasma 
viremia on highly active antiretroviral therapy 
(HAART) [4, 5]. These cells may be particularly suited 
as sanctuaries for virus because HIV-1 DNA (HIV 
DNA), compared to HIV RNA, is less affected by cur-
rent treatment regimens [6-9]. Additionally, these 
nondividing cells differ in many respects from that of 
CD4 lymphocytes making them unique entities for 
long-term persistence of HIV DNA [4, 10]. For in-
stance, mitosis of M/MΦ is not required for nuclear 
import or integration of viral DNA; and M/MΦ not 
only contribute to establishment and persistence of 
HIV-1 infection, they also activate surrounding T-cells 
thus favoring their infection.   
These circulating monocytes traffic through tis-
sue and to the central nervous system (CNS) and dif-
ferentiate into tissue macrophages. This provides a 
basis for theorizing that M/MΦ may contribute to the 
ongoing persistence of HIV-1 in these sites [11]. 
Monocyte trafficking to the CNS is hypothesized to be 
an underlying event in neuropathogenesis of 
HIV-1-associated dementia (HAD) [12-14]. Our recent 
observation of high HIV DNA levels in subjects with 
HAD, even among those with undetectable plasma 
HIV-1 RNA levels (VL), highlights the significance of 
PBMC HIV DNA in the pathogenesis of HAD [15]. We 
performed the prior study on subjects who were on 
HAART, therefore the question remains regarding the 
significance of HIV DNA in HAD pathogenesis before 
beginning therapy. In the prior study, our data sug-
gested that HIV DNA was predominantly in 
CD14/CD16 M/MФ [15]. Therefore to further assess 
the importance of CD14/CD16 phenotype, the current 
study attempts to address the question whether a spe-
cific PBMC subset (M/MФ or CD4 lymphocytes) har-
bors HIV DNA. 
We undertook the current study to test the hy-
pothesis that HIV DNA levels would be elevated in 
cognitively-impaired individuals naïve to HAART; 
and that HIV DNA levels in M/MФ are higher than in 
CD4 lymphocytes in subjects with HAD compared to 
those with no dementia (ND). We hypothesize that an Int. J. Med. Sci. 2007, 4 
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association of HIV DNA with HAD before starting 
HAART would further implicate HIV DNA in the 
neuropathogenesis of HAD likely due to the presence 
of virus in M/MФ that traffic to the CNS. The work 
was completed using a cohort in Bangkok, Thailand, 
which was established to characterize cognition 
among individuals initiating HAART for the first time 
as the country rapidly escalated access to antiretrovi-
ral drugs.   
2.  METHODS 
Subjects and Clinical Data.  
We established a longitudinal neuroAIDS cohort 
within the Southeast Asia Research Collaboration with 
the University of Hawaii (SEARCH) to characterize 
HIV-1-related cognitive dysfunction among individu-
als in Bangkok infected with the most commonly 
identified subtype in Thailand, recombinant circulat-
ing form (CRF) 01_AE. The protocol and consent 
forms were approved by the Ethical Review Commit-
tee and Institutional Review Board of the participating 
institutions. The SEARCH institutions involved in this 
project included the University of Hawaii, 
Phramongkutklao Hospital (PMK), and the Armed 
Forces Research Institute of Medical Sciences 
(AFRIMS), the latter two located on the same campus 
in Bangkok, Thailand. Study volunteers were enrolled 
at PMK, a large, tertiary care teaching hospital that is 
administered by the Royal Thai Army, which provides 
care for all Thai nationals regardless of military affilia-
tion. The study enrolled Thai individuals living in 
Bangkok with HAD, ND, and HIV-1-seronegative 
controls matched for age, education, and gender. 
HIV-1-infected subjects were also matched for CD4 
cell counts. The seronegative controls were enrolled 
and completed identical neuropsychological tests as 
the HIV-1-infected individuals because no Thai nor-
mative data were available to analyze the results. All 
individuals had minimal/distant or no exposure to 
illicit drug use with negative urine toxicology screens 
on two occasions within 30 days prior to enrollment. 
Subjects were all seronegative for hepatitis C virus, 
free of neurological or psychiatric illnesses including 
major depression, and did not have central nervous 
system opportunistic infection, active opportunistic 
infection in any organ system, pre-existing or known 
learning disability, or past brain trauma. Individuals 
thought to have cognitive impairment were referred 
for study participation from the outpatient neurology 
and infectious diseases clinics at PMK or from other 
hospitals/clinics. Matched HIV-1-infected individuals 
without HAD were then recruited. 
The protocol neurologist (P. S.) established a di-
agnosis of HAD using standard-of-care approaches for 
Thailand. In general, the evaluation included partici-
pant and proxy informant reports of symptoms and 
function, the HIV macroneurological examination as 
used in the Adult AIDS Clinical Trails Group (AACTG, 
NIAID), bedside cognitive testing (including assess-
ment of orientation, motor and psychomotor speed, 
memory, executive functioning, and visuospatial skill), 
and the international HIV-1 Dementia Scale [16]. All 
participants with HAD were further evaluated to 
rule-out other causes of cognitive impairment includ-
ing gadolinium-enhanced brain MRI. If clinically in-
dicated, individuals underwent a lumbar puncture to 
exclude opportunistic brain infection, however of the 
eight lumbar punctures that were performed, no op-
portunistic infections were found. Similarly, even 
though HIV-1-infected subjects had advanced immu-
nosuppression, there were no individuals who had 
any history of any opportunistic infections, including 
in the CNS. After enrollment, all participants were 
evaluated with a modified version of the WHO Inter-
national HIV-1 neuropsychological battery [17]. We 
selected this battery as it was designed to minimize 
cultural bias and was utilized in a prior study con-
ducted in Bangkok; therefore feasibility was estab-
lished [17]. We substituted the Brief Visual Memory 
Test-revised for the Picture Memory Test for logistical 
reasons as the latter required immediate and consis-
tent computer and internet access. We assessed de-
pressive symptoms with the Thai Depression Inven-
tory (TDI) which was previously validated in Thailand 
[18]. The assessment was a clinical assessment made 
by the protocol neurologist (P. S.) at the time of clini-
cal evaluation using the TDI, patient interview, and 
patient and proxy information to assist in this assess-
ment. 
We validated the diagnosis of HAD by reviewing 
the first 27 HIV-1 cases enrolled in a consensus panel 
consisting of an HIV neurologist, the study HIV neu-
ropsychologist (R. P.) and the principal investigator of 
the cohort (V. V.). We prepared case summaries con-
sisting of all clinical and neurological data. Individual 
raw neuropsychological scores were then plotted over 
3 box plot distributions of seronegative controls, indi-
viduals with HAD, and those with ND. In a blinded 
fashion, we determined a consensus diagnosis of HAD 
or ND and reached consensus with the diagnosis de-
termined by our Thai colleague on 100% of the ND 
cases. Among the HAD cases, the consensus panel 
was congruent in 70% of the cases with the remaining 
cases felt to be either mild dementia or minor cogni-
tive motor disorder, with an overall congruence ex-
ceeding 85%. The consensus panel was convened to 
validate the diagnosis by the Thai neurologist and not 
to substitute it. Therefore, since an excellent congru-
ence was achieved, we completed the analysis using 
the original diagnoses for the purpose of this evalua-
tion. 
Viral load and CD4 lymphocyte counts were 
performed at AFRIMS, which maintains a Certificate 
of American Pathologists for these tests. Viral sub-
types were determined by ELISA serotyping using 
V3-CM237 (Thai subtype B) and V3 CM242 (subtype E) 
peptides, which distinguishes HIV-1 subtype B and E 
infection in Thai individuals and confirmed by se-
quencing, when indicated [19, 20].   
Specimens and HIV DNA Assay.  
At entry into the cohort, PBMC were isolated and 
stored frozen in dimethyl sulfoxide from blood Int. J. Med. Sci. 2007, 4 
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(ethylenediaminetetraacetic acid tube). DNA was ex-
tracted from an aliquot of frozen PBMC (5 X 106 cells), 
as previously reported [15]. HIV DNA, normalized to 
the number of copies of HIV-1 DNA per 106 cells, was 
then measured using real-time polymerase chain reac-
tion (PCR), as previously described [15]. We per-
formed all real-time PCR assays in triplicate using in-
dependent standard curves generated to measure 
relative HIV DNA copy number and cellular equiva-
lent genomic DNA. The plasmid used to generate the 
standard curves was designed with a single copy each 
of HIV-1 and a housekeeping gene, βglobin. We used 
two primer sets to distinguish amplification of the two 
genes: HIV gag (conserved 296 base pair product for 
subtypes A and B) and βglobin (330 base pair product). 
The PCR master mix consisted of either the HIV or 
βglobin primers and probe sets, 1x iQ supermix (Bio-
Rad Laboratories, Hercules, CA), 100 ng DNA, and 
water (final volume 25 μL) with the following condi-
tions: initial denaturation for 3 min followed by 45 
cycles of 95°C/10 seconds, 57°C/30 seconds; with fi-
nal extension of 72°C/2 min. We used non-HIV-1 in-
fected genomic DNA for a negative control and DNA 
from three HIV-1 infected cell lines (8E5, OM10.1, and 
ACH-2; NIH AIDS Research and Reference Reagent 
Program, NIH, Bethesda, MD) as positive controls. 
The HIV-1 primers were tested on HIV-1 clades A, E, 
and B; and demonstrated equivalent amplification of 
the target gene. 
Separation of PBMC Subsets and HIV DNA Analay-
sis.  
Because HIV DNA is present in both lympho-
cytes and monocytes, we were interested in assessing 
whether more HIV DNA was in one particular PBMC 
subset versus the other. We previously measured HIV 
DNA in PBMC subsets from individuals from a dif-
ferent cohort and showed that there were higher levels 
in M/MΦ compared to CD14- cells in those diagnosed 
with HAD versus those with ND [15, 21]. The same 
procedures were performed on the specimens from 
HIV-1-positive subjects for the current study from 
which adequate numbers of cells were available to 
recover reasonable quantities of cells in the subsets. To 
separate the cells, we used RosetteSep (Stemcell 
Technologies, Vancouver, BC, Canada) combined with 
magnetic beads. Initially a CD14- subset from a small 
aliquot of blood, which includes CD4 lymphocytes, 
was isolated with beads; with the remaining cells 
separated into CD14+/CD16+ by enrichment and bead 
separation. An aliquot of the sorted cells was then 
analyzed by flow cytometry (FACSCalibur, Becton 
Dickinson, San Jose, CA) to verify the phenotype in 
each subset. The cells were analyzed using FlowJo 
software (Tree Star Inc, San Jose, CA) following stain-
ing with the following antibodies (BD Biosciences, San 
Jose, CA): murine anti-human antibodies, 
FITC-conjugated anti-CD14, PE-conjugated anti-CD16 
(3G8; PharMingen), PerCP-conjugated anti-HLA-DR, 
and isotype controls. Total DNA was isolated from 
each subset and HIV DNA measured as described 
above.  
Statistical Analysis.  
We used logistic regression models to examine 
the independent effect of HIV DNA on HAD vs. ND 
with the Likelihood-Ratio test on the odds-ratio. 
Analyses were conducted using SAS 9.0 (SAS Institute, 
Cary, N.C.) with a p-value <0.05 interpreted as a sig-
nificant result. A two sample t test for the educa-
tion/age/CD4/VL variables and Fisher's Exact test for 
the gender variable were used. 
Figure 1. HIV DNA in Subjects with HAD vs. Non-HAD. 
Log10 HIV DNA levels in subjects with HAD (n=15; me-
dian=4.27) are higher than those without HAD (ND, n=15; 
median=2.28), p<0.001. 
 
3.  RESULTS 
Sixty individuals entered the study (n=15 each 
for the HAD and ND groups and n=30 for HIV-1 
seronegative controls); matched for age, gender, and 
years of education, Table 1. All participants were Thai 
nationals with the majority of the participants being 
female. The HIV-1-seropositive subjects (n=30) were 
HAART-naïve initially and had relatively low CD4 
cell counts prior to initiation of therapy, Table 1. All of 
the HIV-1-infected individuals were infected with 
circulating HIV-1 subtype (CRF) 01_AE. In subjects 
with HAD, compared to those with ND, the median 
(IQR) CD4 cell counts were 21 (6-74) cells/ μL and 39 
(16-71) cells/ μL, respectively, with no difference be-
tween the two groups, p=0.775. As would be expected, 
in treatment-naïve patients with low CD4 cell counts, 
the log10 HIV-1 plasma RNA levels were relatively 
high with no difference in between the two groups 
(median 5.28 and 5.33 for HAD and ND, respectively), 
p=0.811.  
Comparing subjects with and without HAD, we 
found significantly higher log10 HIV DNA copies per 
106 PBMC in the HAD group [n=15; median 4.27 (2.10 
to 5.28)] versus the ND group [n=15; 2.28 (0.69 to 
4.30)],  p<0.001, Table 1. The calculated log10 HIV 
DNA/106 PBMC and medians for ND and HAD indi-
viduals is shown in Figure 1. In an unadjusted logistic 
regression model, we identified an association of HIV 
DNA to HAD resulting in an odds ratio of 1.841 (95% 
confidence interval, CI, 1.286-2.635), p<0.001, with the 
odds ratio representing a one unit increase in log10 
HIV DNA copies per 106 cells. This effect was un-
changed in a multivarate model adjusting for plasma Int. J. Med. Sci. 2007, 4 
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HIV RNA levels (odds ratio 1.867, 95% CI 1.297-2.688). 
As expected, HIV DNA was not detected in any of the 
HIV-1 seronegative control subjects.   
 
Table 1. Demographic and Laboratory Parameters 
 HIV-1-Seronegative (n=30)  HAD (n=15)  ND (n=15)  p 
Age (years) [mean (SD)]  34.1 (9.6)  33.1 (8.6)  33.7 (8.0)  0.947 
Years of education [Mean (SD)]  7.6 (1.8)  6.9 (2.3)  6.6 (1.7)  0.186 
Female/Male 18/12  9/6  10/5  0.904 
CD4 cell count (cells/μL)       
Median (IQR)  797.6 (679-1012)  21 (6-74)  39 (16-71)   
Log10 HIV-1 RNA (copies/mL) 
Median (IQR) 
 
Not applicable 
 
5.28 (5.04-5.54) 
 
5.33 (5.08 to 5.53) 
 
0.811 
Log10 HIV DNA (copies/106 PBMC) 
Median (IQR) 
 
Not applicable 
 
4.27 (2.10 to 5.28) 
 
2.28 (0.69 to 4.30) 
 
<0.001 
HAD: HIV-1-associated dementia; ND: no dementia 
Table 2. HIV DNA Copy and Total Burden in PBMC and Subsets 
HIV DNA Copy per  Total HIV DNA Copy Calculated From  Diagnosis 
PBMC   CD14/CD16   CD4  PBMC   CD14/CD16   CD4 
Ratio* 
HAD 4.10X10-2 1.27X10-2 1.92X10-4 2.50X108 1.48X106 3.5X104 >1 
HAD 1.34X10-2 1.25X10-2 1.06X10-4 9.91X107  6.18X105  6.28X104  >1 
HAD 2.09X10-2  2.16X10-2  1.59X10-4  1.23X108  3.15X106  9.38X103  >1 
HAD 2.00X10-2 1.24X10-2 5.30X10-4 1.08X108  1.79X106  5.72X104  >1 
HAD 3.35X10-2  5.75X10-2 2.16X10-4 2.41X108  4.85X107 7.78X104 >1 
Non-HAD 1.89X10-4 9.10X10-6 1.56X10-4 1.25X106 7.46X102 1.03X106 <1 
Non-HAD 4.45X10-3 3.77X10-4 4.29X10-3 2.83X107 2.70X104 1.62X106 <1 
Non-HAD 4.68X10-3 3.13X10-4 4.08X10-3 1.54X107 2.41X104 5.39X105 <1 
Non-HAD 2.00X10-2 1.06X10-3 1.94X10-2 1.10X108 6.76X104 6.40X106 <1 
*Ratio of CD14/CD16 to CD4 > 1.00 denotes total higher HIV DNA levels in CD14/CD16 compared to CD4 subsets 
Figure 2. Phenotypic Expression of CD14
+ and CD14
- Sorted Subsets. Cells from sorted fractions were stained for CD14. A, 
B) Two examples of CD14-stained sorted cell populations from monocyte fractions from two different subjects demonstrating 
the majority of cells isolated were CD14
+ (82.3% and 92.3%); C) CD14-negative subset showing low CD14-staining (0.49%).  
 
 
A limited number of individuals (HAD n=5; ND 
n=4) had analyses of PBMC subsets in which an ade-
quate number of cells was available for separation. 
Using flow cytometry (monocyte & CD4/CD8 per-
centages) and data from sorted cells, we estimated the 
total HIV DNA copies from CD14/CD16 and CD4 
subsets. An assumption was made whereby HIV DNA 
measurements from the CD14- subsets were primarily 
from CD4 lymphocytes. The efficiency of our sorting 
procedure is depicted in Figures 2A & 2B, where 
greater than 80-90% of isolated monocyte subsets were Int. J. Med. Sci. 2007, 4 
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CD14+. Less than 1% of cells from the CD14- subset 
were positive for CD14, Figure 2C. By extrapolating 
from the calculated values, HIV DNA levels in PBMC 
were relatively high in all individuals diagnosed with 
HAD with the highest in the CD14/CD16 subsets 
compared to CD4 subsets, Table 2. We initially esti-
mated HIV DNA copy per PBMC; per CD14/CD16 
cell; and per CD4 lymphocyte, Table 2. We then esti-
mated the total HIV DNA contribution from each 
subset using the flow data and complete blood counts 
obtained at the same time the blood was collected. In 
this analysis, the total HIV DNA contribution from 
CD14/CD16 cells was higher than the HIV DNA con-
tribution from CD4 cells in subjects with HAD, Table 2, 
which was not apparent in subjects without HAD. In 
order to estimate differences in the HIV DNA contri-
bution from the two subsets, the ratios of HIV DNA 
from CD14/CD16 subsets to HIV DNA from CD4 
subsets were calculated. This resulted in ratios sig-
nificantly higher from those with HAD (n=5; me-
dian=188.5) compared to those with ND (n=4; me-
dian=0.0059), p<0.029, Table 2. 
4.  DISCUSSION 
Current antiretroviral therapy for HIV-1 focuses 
on eradication of the virus from plasma. In contrast to 
the cytotoxic effects of HIV-1 on lymphocytes, 
HIV-1-infection usually leads to chronic infection in 
M/MΦ. Recent studies suggest that PBMC HIV DNA 
may be a marker for HIV-1 disease progression [22-25]. 
Our laboratory previously reported the presence of 
high HIV DNA in PBMC as a risk for HAD in 
HAART-experienced individuals; and preliminary 
analyses suggest that the majority of this HIV DNA 
may be in circulating M/MФ [15]. We demonstrated 
that this effect was independent of plasma HIV-1 RNA 
levels by a separate analysis of HIV DNA in individu-
als with undetectable plasma VL. We now confirm our 
findings in a different cohort who are naïve to 
HAART and hypothesize that high HIV DNA levels 
are an important factor in HAD pathogenesis. 
In the current study, we found the effect of HIV 
DNA on HAD was independent of age and current 
CD4 count at the time of recruitment, which is similar 
to what was found previously in patients on effective 
antiretroviral therapy. The HIV DNA data suggesting 
a higher contribution from the monocyte/macrophage 
subsets in patients with HAD are limited by the small 
number of specimens available. The cohort established 
in Thailand provided a unique opportunity to test our 
hypothesis of the role of HIV DNA in HAD. We were 
able to enroll age-, education-, and gender-match 
HIV-1 seronegative individuals as controls to establish 
normative data for the current study, which have not 
previously been established in Thailand. Additional 
data in PBMC subsets are needed to assess the impor-
tance of HIV DNA in the pathogenesis of HAD. Other 
limitations of the current study include the assump-
tion that the CD14- subsets were composed mainly of 
CD4 lymphocytes. The calculations of HIV DNA cop-
ies in the PBMC subsets are based on extrapolated 
values. To confirm the findings, future experiments 
are planned to use a cell sorter to isolate specific cell 
populations. 
While the mechanism by which HIV DNA leads 
to neurocognitive problems remains unclear, we pro-
pose that our results demonstrating an association in 
HAART-naïve patients strengthens the relationship of 
HIV DNA to HAD neuropathogenesis. Even though 
the mechanisms linking HIV DNA to HAD patho-
genesis are not fully known, studying HIV DNA in 
PBMC subsets such as memory and naïve CD4 
T-lymphocytes, and CD14+ monocytes may provide 
clues to HIV-1-associated neuropathogenesis [6]. Oth-
ers have shown that HIV DNA was detected in both T 
lymphocytes and monocytes in severely immuno-
compromised subjects on HAART, but with higher 
levels in monocytes [26]. In another study, monocytes 
were identified as the predominant cellular reservoir 
of virus in the majority of subjects who had been on 
HAART for longer than 2 years [24]. Calcaterra et al. 
found higher levels of HIV DNA in monocytes than in 
CD4+ lymphocytes in a subset of non-viremic patients 
[24]. Pertinent to our results was the finding that three 
patients in the Calcaterra analyses had HIV DNA 
titers in monocytes that were at least six-fold higher 
than in CD4+ lymphocytes [24]. 
Activated CD4+ lymphocytes, once infected, are 
rapidly killed by HIV-1 while M/MФ are less affected 
by the cytopathic effect of the virus [27-29]. Several 
studies demonstrated the presence of HIV-1 in M/MФ 
in HAART-treated patients, even among those with 
consistently undetectable viral loads [15, 30-32]. The 
presence of elevated HIV DNA levels in PBMC in 
HAART-naïve and HAART-treated individuals with 
HAD relative to ND suggests a critical need to identify 
the interrelationship among M/MΦ, HIV DNA, and 
HAD. This may expose underlying mechanisms to 
explain the continued prevalence of HAD in the era of 
HAART. Since HIV DNA in M/MФ persists while 
individuals are on HAART and since monocytes likely 
play a critical role in HIV-1 neuropathogenesis, these 
M/MФ may be important cellular reservoirs of virus 
[33, 34]. Future studies are planned to assess other 
markers of monocyte/macrophage activation other 
than CD14/CD16 to determine the importance of HIV 
DNA in M/MФ in the pathogenesis of HAD.   
In summary, our findings confirm the association 
between HIV DNA and dementia in HIV-1-infected 
patients even prior to instituting HAART. We also 
demonstrate that this effect does not appear to relate 
to age, CD4 count, or plasma HIV-1 RNA levels. The 
current study provides new evidence supporting the 
hypothesis that HIV DNA may be an important factor 
in HIV-1 neuropathogenesis. Further research is nec-
essary to understand the mechanisms underlying this 
relationship, and particularly, to evaluate longitudinal 
cohorts to determine the prognostic significance of 
HIV DNA and its relationship to HAD incidence. 
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